anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Assessing pain in non-verbal patients is challenging, often depending on clinical judgment which can be unreliable due to fluctuations in vital signs caused by underlying medical conditions. To date, there is a notable absence of objective diagnostic tests to aid healthcare practitioners in pain assessment, especially affecting critically-ill or advanced dementia patients. Neurophysiological information, i.e., functional near-infrared spectroscopy (fNIRS) or electroencephalogram (EEG), unveils the brain's active regions and patterns, revealing the neural mechanisms behind the experience and processing of pain. This study focuses on assessing pain via the analysis of fNIRS signals combined with machine learning, utilising multiple fNIRS measures including oxygenated haemoglobin (ΔHBO2) and deoxygenated haemoglobin (ΔHHB). Initially, a channel selection process filters out highly contaminated channels with high-frequency and high-amplitude artifacts from the 24-channel fNIRS data. The remaining channels are then preprocessed by applying a low-pass filter and common average referencing to remove cardio-respiratory artifacts and common gain noise, respectively. Subsequently, the preprocessed channels are averaged to create a single time series vector for both ΔHBO2 and ΔHHB measures. From each measure, ten statistical features are extracted and fusion occurs at the feature level, resulting in a fused feature vector. The most relevant features, selected using the Minimum Redundancy Maximum Relevance method, are passed to a Support Vector Machines classifier. Using leave-one-subject-out cross validation, the system achieved an accuracy of 68.51%±9.02% in a multi-class task (No Pain, Low Pain, and High Pain) using a fusion of ΔHBO2 and ΔHHB. These two measures collectively demonstrated superior performance compared to when they were used independently. This study contributes to the pursuit of an objective pain assessment and proposes a potential biomarker for human pain using fNIRS.
A nail polish with a crack and color changing effect includes a polymer, a solvent, a plasticizer, a pigment, a silica and a thermochromic powder. The polymer accounts for 10%-30% of the total weight and contains nitrocellulose and resin. The solvent accounts for 44%-64% of the total weight. The plasticizer accounts for 3%-8% of the total weight. The silica accounts for 8% of the total weight. The pigment accounts for 10%-20% of the total weight. The thermochromic powder accounts for 5% of the total weight. The nail polish with a crack and color changing effect composed by the aforementioned components may generate cracks after being applied and dried and also generate a color changing effect with the changing of the temperature of nails.
In some aspects, the disclosure provides methods of treating cancer or an infection. In some aspects, the disclosure provides methods of enhancing the efficacy of treatment with an immune checkpoint inhibitor. In some embodiments the methods comprise administering a complement inhibitor and an immune checkpoint inhibitor to a subject with cancer or an infection. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor. In some embodiments the methods comprise determining whether the subject is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor based on an assay of a complement system biomarker in the subject or in a sample obtained from the subject.
In this study, 36 individuals, diagnosed with scleroderma by a rheumatologist at Gazi University, were included. In the study approved by the Gazi University Clinical Research Ethics Committee (21.09.2020, Decree No: 635) and planned by the Declaration of Helsinki, consent forms were sent to all participants to confirm that they were volunteers. Demographic information of the individuals was obtained. The Canadian Occupational Performance Measure (COPM) was used to identify occupational problems and to implement a person-centered program. This information was obtained by submitting online forms. The videos were prepared by a team of physiotherapists, occupational therapists, and rheumatology doctors. The program manager was an occupational therapist. 29 people completed the 8-week program, which included 40-50 minute videos and assignments (keeping a pain diary, creating an exercise routine, etc.). At the end of the program, individuals were reminded of the difficult occupations again so that the Canadian Occupational Performance Measure could be re-scored. Initially, the open-ended question "In which ways did the program contribute to you?" was asked. Individuals were evaluated in the first and last week of the program and the results were compared. These evaluations and interventions were made during the Covid-19 pandemic.
The investigators will conduct a randomized controlled trial in patients aged 18 and older where the treating clinician is ordering a CT/NG test. Clinicians will be approached by a research assistant while they are in the ED and asked whether a CT/NG swab will be ordered and if CT/NG is in the differential diagnosis. Then, potentially eligible patients will be approached and asked for consent to enroll. For patients that consent, simple randomization procedure (i.e. random number generator) will be used to assign patients to either immediate test results or delayed test results. Typically, in the ED these tests are ordered for diagnostic rather than screening purposes (symptoms of vaginal discharge, abdominal pain, etc). Patients will be randomized to batched testing with the Roche AMPLICOR CT/NG (standard of care, control group) or immediate testing of clinical specimens with Cepheid CT/NG with real-time result reporting (within 90 minutes) to the treating clinician in the ED. Patient interview and clinician survey will be conducted to ascertain perceptions of illness and the test. A follow up interview will be conducted with the patient to determine clinical and public health outcomes.

A validation of the Cepheid CT/NG test will be conducted against the hospital standard of care on \</= 40 pilot participants. Pilot participants will be asked to provide 2 endocervical swabs and a urine specimen. All surveys and interviews will be conducted on pilot patients.

While many outcomes can be measured in this study, the investigators will power this study to reduce the overtreatment rate with antibiotics. Assuming a baseline overtreatment rate of 88% (# treated with antibiotics/# without disease), to reduce this rate by 50% (to 44%), at a power of 80% and alpha of 0.05, the investigators will need to enroll 42 patients (21 controls and 21 study patients) with negative tests. Given an estimated positive rate of 6%, and that approximately 50% of patients who receive these tests for any reason will be treated empirically with antibiotics, the investigators think that enrolling a total of 70 patients with full data (enrollment survey, clinician survey, and follow up survey) would be sufficient to identify trends with this subject matter. Due to the sensitive nature of the subject matter and the high percentages of lost-to-follow up with ED patients, the investigators estimate approximately 50% will have incomplete data. Therefore, the investigators request to enroll 150 patients in the study.
PURPOSE:To provide a carcinostatic agent containing an isoprenyl compound in combination with bleomycin or adriamycin, as active components. CONSTITUTION:The objective carcinostatic agent contains bleomycin or adriamycin in combination with an isoprenyl compound (e.g. the compound of formula I -formula V), as active components. The content of the isoprenyl compound is selected to be 10mg-2g/kg daily for oral administration and 4mg- 1g/kg daily for injection, based on the normal administration dose of bleomycin or adriamycin. It is administered in the form of tablet, granule or powder in the case of oral administration, and especially, the granule and powder can be encapsulated to enable the administration of unit dose. A synergistic effect can be attained and the activity of the active component can be promoted by the combined use of both components.
PURPOSE:The titled substitute milk suppressing more extremely occurrence of diarrhea than an existing substitute milk, lowering mortality rate, obtained by blending plasma powder or plasma protein powder of cattle and pig with one or more of dried dairy product, fats and oils, saccharide, vitamins and minerals. CONSTITUTION:An anticoagulant such as sodium citrate, etc., is added to blood of healthy cattle and pig and hemocytes are removed by centrifugal separation to give plasma. Soluble salts, saccharides, low-molecular weight admixed protein, amino acids, etc., are removed from the plasma by ultrafiltration method, salting-out method, etc., and a protein fraction is concentrated to give plasma protein. The plasma powder or the plasma protein powder is added to substitute milk so that the substitute milk contains 5-50wt% plasma powder or plasma protein powder, to give substitute milk for piglet and calfs. About 5-13wt% of the substitute milk is dissolved in water or warm water and the solution in amount corresponding 1-12wt% weight of the piglet and calfs is given to them separated from the mothers once - three times daily. Consequently, the piglet and the calfs grow extremely favorably.
INTRODUCTION: The improved quality of care and increased drug availability have shifted the goal of treating people with hemophilia from life-threatening bleeding prevention to joint health preservation and quality of life amelioration. Many tools are now available to the clinician in order to optimize the management of hemophilic arthropathy.
AREAS COVERED: This paper reviews the pivotal role of ultrasound evaluation in early detection of joint bleeding and differential diagnosis of joint pain, with a focus on the feasibility of a long-term monitoring of joint health through the use of artificial intelligence and telemedicine. The literature search methodology included using keywords to search in PubMed and Google Scholar, and articles used were screened by the coauthors of this review.
EXPERT OPINION: Joint ultrasound is a practical point-of-care tool with many advantages, including immediate correlation between imaging and clinical presentation, and dynamic evaluation of multiple joints. The potential of telemedicine care, coupled with a point-of-care detection device assisted by artificial intelligence, holds promises for even earlier diagnosis and treatment of joint bleeding. A multidisciplinary approach including early intervention by physical medicine and rehabilitation (PMR) physicians and physiotherapists is crucial to ensure the best possible quality of life for the patient.
Cerebral palsy (CP) is a neurologic injury that impacts control of movement. Individuals with CP also often develop secondary impairments like weakness and contracture. Both altered motor control and secondary impairments influence how an individual walks after neurologic injury. However, understanding the complex interactions between and relative effects of these impairments makes analyzing and improving walking capacity in CP challenging. We used a sagittal-plane musculoskeletal model and neuromuscular control framework to simulate crouch and nondisabled gait. We perturbed each simulation by varying the number of synergies controlling each leg (altered control), and imposed weakness and contracture. A Bayesian Additive Regression Trees (BART) model was also used to parse the relative effects of each impairment on the muscle activations required for each gait pattern. By using these simulations to evaluate gait-pattern specific effects of neuromuscular impairments, we identified some advantages of crouch gait. For example, crouch tolerated 13 % and 22 % more plantarflexor weakness than nondisabled gait without and with altered control, respectively. Furthermore, BART demonstrated that plantarflexor weakness had twice the effect on total muscle activity required during nondisabled gait than crouch gait. However, crouch gait was also disadvantageous in the presence of vasti weakness: crouch gait increased the effects of vasti weakness on gait without and with altered control. These simulations highlight gait-pattern specific effects and interactions between neuromuscular impairments. Utilizing computational techniques to understand these effects can elicit advantages of gait deviations, providing insight into why individuals may select their gait pattern and possible interventions to improve energetics.
Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.
PROBLEM TO BE SOLVED: To obtain a material suitable for a crown having a high strength, light transmitting properties and a low melting temperature by specifying a component composition and including enstatite as a main crystal phase therein. SOLUTION: This crystallized glass comprises the following components in amounts expressed in terms of wt.%: 40-60wt.% SiO2 , 20-35wt.% MgO, 4-15wt.% TiO2 , 0-9.0wt.% Na2 O and/or K2 O and 4-25wt.% La2 O3 and/or Y2 O3 . The components are capable of alone or synergistically performing the following actions: The viscosity of the glass is made appropriate and the forming is facilitated. The light transmitting properties are improved to promote the nitrification. The thermal expansion coefficient is reduced to prevent the refractive index from deterioration. It is essential that the crystallized glass contains enstatite as a main crystal phase and a higher strength cannot be realized if the enstatite is not contained therein.
The invention discloses a traditional Chinese medicine preparation used for treating cutaneous hemangioma. The invention belongs to the field of traditional Chinese medicine. the preparation is prepared from medicine materials of, by weight: 8 parts of tree peony root-bark, 12 parts of tuckahoe, 10 parts of tuber fleeceflower root, 6 parts of redroot gromwell, 6 parts of cape jasmine, 8 parts of wenchow turmeric root tuber, 8 parts of common threewingnut root, 15 parts of lightyellow sophora root, 12 parts of common cnidium fruit, and 10 parts of white peony root. According to the invention, the traditional Chinese medicine preparation is prepared from pure natural traditional Chinese medicine materials. The curative effect is definite. No toxic or side effect is caused. With the preparation, cutaneous hemangioma can be effectively cured, and is not easy to reoccur.
Systemic onset Juvenile Idiopathic Arthritis (soJIA) is a type of arthritis (inflammation of the joints) that occurs with other symptoms including fever, swollen lymph nodes (glands), rash, and body aches. Because soJIA can be difficult to treat, children with soJIA can have severe problems from long-term use of steroids (prednisone). These problems include low bone density (weak bones), fractures, failure to grow properly, and large weight gain. The arthritis that occurs in soJIA often causes damage to many joints. This can make it hard to move around or do basic tasks like dressing. Also, a life-threatening illness called Macrophage Activation Syndrome (MAS) can occur when starting, stopping, or changing drugs that are used to treat soJIA.

SoJIA can be hard to treat and many children with soJIA do not respond to drugs that work for other kinds of arthritis. Research doctors have studied a chemical signal called IL-6 that the body uses to manage inflammation. This signal has been found to be very high in patients with active soJIA. A drug called tocilizumab (TCZ) has been designed to block IL-6. For about 6 years, TCZ has been tested in Japan for treating soJIA. It is now being tested in studies in the United States. These studies can have very strict rules for enrolling patients. This trial is a single-patient research study for a subject who otherwise does not meet the rules for enrollment in ongoing trials.
Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt% and 80 wt% of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.
The floss is comprised of one or more strands of a tensilized polytetrafluoroethylene. The polytetrafluoroethylene is tensilized by stretching with heating to increase the tensile strength and to decrease elongation. The floss is readily grippable since it has an irregular surface. The polytetrafluoroethylene is made to have an irregular surface by having a solid incorporated into the fiber structure. The solid has a diameter of from about submicron size up to about 125% of the thickness diameter of the fiber. The floss will have a coefficient of friction of more than about 0.08. There is an acceptable grippability without the need for a coating. In addition, the solid that is incorporated into the fiber can be a bioactive material for delivery of the bioactive material to the teeth and gums during flossing.
Patients undergoing non-cardiac surgery with abnormal preoperative Estimated Glomerular Filtration Rate (eGFR). eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates. As eGFR is not accurate in the setting of dialysis, patients receiving dialysis for at least 90 days prior to their surgical procedure will also be included as a separate eGFR category.
Pharmaceutical compositions having anti-bacterial, anti-viral, anaesthetic, analgesic and anti-leukopenic effects comprise a neutral salt of lysozyme with a non-toxic, stable, inorganic or organic acid and an anti-histaminic compound which is completely compatible with said salt of lysozyme.  The composition may contain 50-1000 parts by weight of the lysozyme salt per part by weight of anti-histaminic compound.  Antihistaminics specified include chlorpheniramine, polaramine, parabromdylamine, carbinoxamine, diphenhydramine and pyrilamine.  Salts of lysozyme and the antihistaminic may be formed with hydrochloric, sulphuric, phosphoric, acetic, maleic, citric and tartaric acids. The compositions may also contain a solid or liquid pharmaceutical carrier and may be formulated as tablets and capsules, preferably enteric-coated, or as a sterile, isotonic, aqueous solution buffered to pH 4-6.5 with a phosphate, citrate or tartrate buffer.  Such a solution may additionally contain a non-toxic, water-soluble salt (e.g. Na, Cl, Ca Cl2, Na2SO4 and sodium phosphates) and/or a polymeric material (e.g. polyvinyl pyrrolidone and dextran).
Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
PROBLEM TO BE SOLVED: To restrict postoperative adhesion by arranging a hyaluronic acid gel obtained by irradiating a less water soluble hyaluronic acid gel made of hyaluronic acid alone with one selected from the group of a gamma ray, an electron beam, and the like, to be contained into a medical material for securing ideal biological compatibility and storability. SOLUTION: A hyaluronic acid gel obtained by irradiating a less water soluble hyaluronic acid gel made of hyaluronic acid alone with one selected from the group of gamma rays, an electron beam, plasma, an optical pulse, and the like, is contained into a medical material. In this process, the solubility is 50% or more in a neutral aqueous solution of 37 deg.C for 12 hours. The gel made of the hyaluronic acid alone is one kind selected from the group of a sheet, a film, a tube, and the like. Moreover, the hyaluronic acid gel made of the hyaluronic acid alone and the hyaluronic acid not gelatinized may together be contained. The medical material herein used is an adhesion preventing material or a wound treating material.
Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in "dose modifications". The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination.